Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Stock is 

Investor Overview

Analyst Coverage

Firm Analyst
Needham & Company
Chad Messer Ph.D.
Oppenheimer & Co.
Mark Breidenbach Ph.D.
Piper Sandler
Tyler Van Buren
RBC Capital Markets
Kennen MacKay

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.